We are studying a new treatment, DB-1303, for patients with HER2-low, hormone receptor-positive metastatic breast cancer. The goal is to see if it works better than standard chemotherapy after previous treatments have failed.
We are providing continued treatment for patients who have benefited from Durvalumab in a previous study. The focus is on monitoring safety and tolerability during this ongoing care.
We are studying if vaccinating children with a higher genetic risk for type 1 diabetes against COVID-19 can lower their chances of developing diabetes and related autoimmune conditions. This research aims to see if the vaccine can help protect their health.
We are examining the long-term safety and tolerability of ACP-204 in adults with Alzheimer's Disease Psychosis. This study helps us understand how well patients can handle this treatment over time.
We are investigating the long-term safety and effectiveness of BI 1015550 in patients with pulmonary fibrosis who have previously participated in related studies. This study aims to understand how well the treatment is tolerated and its potential benefits.
We are evaluating a new drug called Prosetin to see how safe it is and how well it is tolerated in people with ALS and healthy volunteers. This study aims to understand its effects on ALS symptoms.
We are studying whether pancreatic enzyme replacement therapy can help patients with unresectable pancreatic cancer gain weight and improve their nutrition. This may enhance their quality of life and ability to handle chemotherapy.
We are studying the safety of efgartigimod given through IV and injection in children with generalized myasthenia gravis. This trial aims to ensure the treatment is safe and well-tolerated.
We are evaluating the long-term safety and effects of NTLA-2001 in participants who have already received this treatment. This study aims to understand how it impacts their health over time.
We are investigating a new treatment, SP-420, for individuals with transfusion-dependent thalassemia or low-risk myelodysplastic syndromes. The study aims to find the right dose and evaluate its effectiveness in reducing excess iron and its safety.
We are studying whether adding isatuximab to iberdomide helps patients with newly diagnosed multiple myeloma achieve better treatment outcomes after stem cell transplantation.
We are investigating how zolpidem affects people with disorders of consciousness, vision impairments, and healthy volunteers. This study aims to uncover why some individuals respond differently to the medication.
We are evaluating a new inhaler that combines Budesonide, Glycopyrronium, and Formoterol for people with COPD. The goal is to see if it improves heart and lung health compared to current treatments.
We are testing a new treatment for patients with advanced or metastatic solid tumors that have specific genetic changes. The goal is to see how well it works and how it affects patients' daily lives.
We are studying whether oral vancomycin can improve liver health in adults and young patients with Primary Sclerosing Cholangitis. The trial will also look at the safety of the treatment and its effects on related health conditions.
We are investigating whether PRGF-Endoret® can effectively reduce pain and enhance quality of life in patients with chronic low back pain due to disc degeneration, compared to standard treatments.
We are testing a new treatment called PIT565 for patients with relapsed or refractory B-cell malignancies. The goal is to see if it can improve outcomes for these patients.
We are exploring how preoperative use of ketorolac and pregabalin affects inflammation and pain in breast cancer patients. This study looks at how these effects may vary based on body weight.
We are studying various treatments for COVID-19 to see if they can reduce death rates and help patients leave the hospital sooner. We also want to find out if these treatments can prevent severe breathing issues.
We are exploring whether a new treatment based on biomarkers can improve kidney function in patients with chronic kidney disease compared to standard care. This study aims to find better ways to manage CKD and its effects.